Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to begin Nasdaq trading Friday.
Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night.
Odyssey began trading on the Nasdaq …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Odyssey, on second try, snags $279M in an IPO
Isomorphic Labs’ $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
Biotech raises $42 million to run Huntington’s disease trial
UCB to acquire maker of antibody treatments for autoimmune diseases
Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price
